Skip to main content
Log in

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dombrowski S, Kostev K, Jacob L (2017) Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—a retrospective analysis of real-world data. Osteoporos Int. doi:10.1007/s00198-017-4051-y

  2. Mamza J, Marlin C, Wang C, Chokkalingam K, Idris I (2016) DPP-4 inhibitor therapy and bone fractures in people with type 2 diabetes—a systematic review and meta-analysis. Diabetes Res Clin Pract 116:288–298

    Article  CAS  PubMed  Google Scholar 

  3. Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A et al (2015) Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. Diabetes Care 38(11):2142–2150

    Article  PubMed  Google Scholar 

  4. Driessen JH, van den Bergh JP, van Onzenoort HA, Henry RM, Leufkens HG, de Vries F (2017) Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study. Diabetes Obes Metab 19(3):421–428

    Article  CAS  PubMed  Google Scholar 

  5. Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16(3):241–249

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. H. M. Driessen.

Ethics declarations

Conflicts of interest

JD, LK, PG and JvB declare that they have no conflicts of interest.

Additional information

A response to these comments can be found at doi:10.1007/s00198-017-4139-4.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Driessen, J.H.M., Knapen, L.M., Geusens, P.P.M.M. et al. Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?. Osteoporos Int 28, 2429–2430 (2017). https://doi.org/10.1007/s00198-017-4120-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-017-4120-2

Navigation